HSBC Holdings’s Arcturus Therapeutics ARCT Stock Holding History

HSBC Holdings’s Portfolio ARCT Stock Details ARCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$394K	Buy	56,895 +4,070	+8%	+$32.1K	﹤0.01%	2391
2026 Q1	$396K	Sell	52,825 -13,306	-20%	-$97.1K	﹤0.01%	2326
2025 Q4	$402K	Buy	66,131 +42,148	+176%	+$455K	﹤0.01%	2404
2025 Q3	$440K	Sell	23,983 -8,385	-26%	-$135K	﹤0.01%	2169
2025 Q2	$425K	Buy	32,368 +9,208	+40%	+$109K	﹤0.01%	2234
2025 Q1	$248K	Sell	23,160 -2,208	-9%	-$35K	﹤0.01%	2497
2024 Q4	$424K	Buy	25,368 +2,673	+12%	+$50.3K	﹤0.01%	2280
2024 Q3	$525K	Buy	+22,695	New	+$486K	﹤0.01%	1982
2024 Q2	–	Sell	-7,656	Closed	-$258K	–	2929
2024 Q1	$258K	Buy	7,656 +1,286	+20%	+$45.6K	﹤0.01%	2537
2023 Q4	$202K	Buy	+6,370	New	+$151K	﹤0.01%	2469

Other funds holding ARCT

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

HSBC Holdings's ARCT Position: Q2 2026 in Review

HSBC Holdings increased its Arcturus Therapeutics (ARCT) stake by 7.7% in Q2 2026, buying an estimated $32.1K and bringing the position to 56,895 shares worth $394K. The position accounts for ﹤0.01% of the portfolio, ranked #2391.

HSBC Holdings first reported a position in ARCT in Q4 2023 and has held it in 10 quarters since. The position peaked at $525K in Q3 2024. 135 funds tracked by Wall St. Rank hold ARCT as of Q2 2026.

HSBC Holdings held 56,895 shares of Arcturus Therapeutics worth $394K as of Q2 2026.
HSBC Holdings bought 4,070 Arcturus Therapeutics shares in Q2 2026, an estimated $32.1K.
Arcturus Therapeutics made up ﹤0.01% of HSBC Holdings's portfolio in Q2 2026, its #2391 holding.
HSBC Holdings first reported a position in Arcturus Therapeutics in Q4 2023 and has held it in 10 quarters since.
HSBC Holdings's Arcturus Therapeutics position peaked at $525K in Q3 2024.
135 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q2 2026.

Based on HSBC Holdings's 13F filing for Q2 2026, filed 14 Aug 2026.